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Abstract  12 
Introduction: Excessive use of uncoupling agents, previously used as weight-loss agents, has 13 
led to the increase of body temperature and death. The aim of the present study was to 14 
evaluate the acute cardiac effects of mitochondrial protonophore in a rat model at a high dose, 15 
and its specific influence on cardiac substrate uptake.  16 
Methods: Eight-week-old male Sprague-Dawley rats were intraperitoneally injected with the 17 
protonophore carbonyl cyanide m-chloro phenyl hydrazone (CCCP; 4 mg/kg) or vehicle 18 
(dimethyl sulfoxide). Blood pressure, heart rate (HR), and systolic function was recorded. 19 
Substrate uptake was monitored by radio-active tracers. 20 
Key findings: Compared to the control group, the respiratory rate and body temperature 21 
increased, the left ventricle was dilated, and systolic function transiently deteriorated in the 22 
CCCP group. There was no difference in blood pressure and heart rate between the two 23 
groups. In cardiac substrate uptake, glucose uptake showed a 95% increase (p < 0.05), and 24 
fatty acid uptake showed a 52% decrease (p < 0.05) in CCCP-administered group. 25 
Conclusion: The deleterious effects on cardiac function and the changes in substrate uptake 26 
were observed when administered with the protonophore at a high dose.  27 
 28 
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Mitochondria are crucial modulators of viability and death in a variety of cell types, and play 32 
important roles in energy production [1-2]. In brown fat cells, mitochondrial respiration is 33 
uncoupled from ATP synthesis and heat is produced instead that the energy from beta-34 
oxidation is converted into ATP [3]. Uncoupling also occurs to some extent in other cell 35 
types. Since the 1940s, several substances including carbonyl cyanide m-chloro phenyl 36 
hydrazone (CCCP) and 2,4-dinitrophenol have been known to act as uncoupling agents [5,6]. 37 
These uncoupling agents have the nature of lipid-soluble acids and provide a bypass pathway 38 
of H+ across the inner mitochondrial membrane as a protonophore. As a result of this short 39 
cut, the proton-motive force is dissipated and ATP cannot be synthesized. Recently, several 40 
lines of evidence showed that at low doses, uncouplers reduced reactive oxygen species 41 
(ROS) [4,7,8], increased energy expenditure [4,7], and improved longevity [4,8].  42 
 43 
Historically, uncoupling agents were used as so-called “weight-loss agents” [9], and their 44 
excessive use due to psychological problems has led to the increase of core body temperature 45 
and even death [10]. These weight-loss agents are also associated with a danger of overuse 46 
due to the image of so-called ideal beauty. The toxic effects of protonophoric mitochondrial 47 
uncouplers have been extensively described [10], and the marked toxicity had motivated its 48 
withdrawal from the market. However, recent evidences of long administration of chemical 49 
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uncoupling [4,7,8] make the agent began to show sings coming life again, for example, as a 50 
patent of the new derivatives for the use of non-alcoholic fatty liver disease. However, 51 
detailed knowledge of the effects of their acute administration at a high dose to the heart, 52 
which is one of most energy-consuming organs, have not been examined.  53 
 54 
We previously reported the uptake of the radioisotope-labeled tracer technetium 99m 55 
Technetium (99mTc)-sestamibi (MIBI) signals in the perfused and excised heart in a rat model 56 
administered a protonophore, CCCP [11]. In the excised hearts of Sprague-Dawley (SD) rats 57 
administered 99mTc-MIBI which is positively charged and distributed into mitochondria 58 
according to the mitochondrial membrane potentials, CCCP decreased the 99mTc-MIBI signals 59 
along with a decrease of in situ ATP and phosphocreatine contents of the heart. In the present 60 
study, we aimed to clarify the acute effects of the protonophore on cardiac function and 61 
cardiac substrate uptake in a rat model, which are the novel points of the present study. 62 




Animals and materials 65 
Eight-week-old male SD rats (body weight 280–290 g) were administered CCCP (Wako Pure 66 
Chemical Industries; Osaka, Japan). Animal care and experimental procedures were approved 67 
by the Institutional Animal Care and Use Committee of Kyoto University (permission no. 68 
MedKyo14184) and conducted following the Guide for Care and Use of Laboratory Animals 69 
published by the United States National Institutes of Health. 99mTc-MIBI and 125I-(p-70 
iodophenyl)-9-R,S-methylpentadecanoic acid (9MPA) were purchased from FUJIFILM RI 71 
Pharma Co. Ltd. (Tokyo, Japan). 18F-deoxyglucose (FDG) was synthesized by Kyoto 72 
University Hospital. CCCP (Wako Pure Chemical Industries, Osaka, Japan) was diluted in 73 
100% dimethyl sulfoxide (DMSO, Wako Pure Chemical Industry, Osaka, Japan) to prepare a 74 
10 mM stock solution.  75 
 76 
Physiological and hemodynamic analysis  77 
Protocol 1: To investigate the physiological and hemodynamic changes in CCCP-78 
administered rats, 8-week-old male SD rats (n = 6) were intraperitoneally injected with CCCP 79 
(4 mg/kg) or vehicle (DMSO; n = 6). Body temperature and blood pressure was recorded at 80 
the rectum at 30 min after the CCCP injection (AD-1687, A&D Company Ltd., Tokyo, Japan). 81 
Blood pressure is determined by the tail-cuff method using a noninvasive automated blood 82 
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pressure apparatus (Softron SBP-200, Softron Co. Ltd., Tokyo, Japan) without anesthesia. 83 
Transthoracic echocardiographic analysis was performed as previously reported [12] using a 84 
Sonos-5500 echocardiograph (Agilent Technologies, Santa Clara, CA, USA) with a 15-MHz 85 
linear transducer. Heart rate (HR), intraventricular septal thickness (IVSd), left ventricular 86 
dimension in the diastolic phase (LVDd), and left ventricular dimension in the systolic phase 87 
(LVDs) were measured with M-mode echocardiography 30 min, 90 min, and 180 min after 88 
CCCP injection, and fractional shortening (FS) was calculated using the following 89 
formula: %FS = [(LVDd –LVDs)/LVDd] × 100. 90 
 91 
Effect of CCCP on the uptake of a glucose and fatty acid radiotracer 92 
Protocol 2: To analyze the effect CCCP on glucose and fatty acid uptake, 18F-deoxyglucose 93 
(FDG) and 125I-9MPA was used, respectively. The rats (n = 6 per group) were fasted 94 
overnight, administered CCCP, and injected with 1 mCi of 18FDG and 20 μCi of 125I-9MPA 95 
simultaneously 45 min later. They were euthanized by decapitation 45 min after the injection, 96 
and the hearts were removed and washed in cold saline. The 1/3 portion of the apical side was 97 
frozen in liquid nitrogen and the radioisotopic activity was measured using a scintillation 98 
counter (Cobra2TM Auto-gamma, Packard) [13, 14]. To measure 18FDG uptake, radioisotopic 99 
activity was measured just after euthanization because the half-decay time of 18FDG is 110 100 
min. To measure 125I-9MPA uptake, radioisotopic activity was measured 48 h after the 101 
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euthanization. The myocardial uptake levels of 18FDG or 125I-9MPA were assessed by direct 102 
measurement using the scintillation counter. The amount of radioisotope incorporated is 103 
expressed as a percentage of the administered radioisotope activity corrected by heart weight 104 
(g). Cross-talk between the two tracers was negligible [13, 14]. 105 
 106 
Washout of 99mTc-MIBI in vivo 107 
Protocol 3: In order to investigate the mechanism of substrate change, we calculated 99mTc-108 
MIBI in vivo to show the changes in mitochondrial function [15, 16, 17]. A dose of 15 MBq 109 
(405.4 μCi) of 99mTc-MIBI was injected into the tail vein under anesthesia with pentobarbital 110 
sodium (10 mg/kg IP). Rats were placed exactly 10 cm from the collimator. Pre-CCCP or 111 
vehicle-administered images (64 × 64 matrix size) were obtained 15 min after the 99mTc-MIBI 112 
injection. Then, CCCP or vehicle was administered intraperitoneally to rats 90 min after the 113 
99mTc-MIBI injection (CCCP: n = 8, vehicle: n = 7). Thereafter, post-CCCP or vehicle-114 
administered images were obtained 180 min after the 99mTc-MIBI injection. To calculate the 115 
rate of myocardial 99mTc-MIBI washout following injection, a region of interest was manually 116 
drawn around the heart and in the mediastinum area between the upper limbs. The myocardial 117 
99mTc-MIBI washout rate (percentage) was calculated using the following equation: (A – 118 
B*DC) / A × 100 (%), in which A was defined as (pre-CCCP or vehicle-administered heart 119 
count − pre-CCCP or vehicle-administered mediastinum count), B was defined as (post-CCCP 120 
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or vehicle-administered heart count − post-CCCP or vehicle-administered mediastinum 121 
count), and DC is the decay coefficient. [15, 16, 17]  122 
 123 
 124 
Statistical analysis 125 
All data are expressed as the mean ± standard error of the mean (SEM). Differences between 126 
the groups were compared using the Kruskal-Wallis post-hoc using Dunn’s test. In all tests, a 127 
value of p < 0.05 was considered statistically significant. 128 




Effects of CCCP on body temperature, hemodynamics, and cardiac function 131 
Body temperature analyzed at 30 min after the CCCP injection was higher than that after 132 
vehicle injection (p = 0.024, Figure 1A), indicating that electron transport was uncoupled by 133 
CCCP. There was no difference in heart rate between CCCP-administered and vehicle-134 
administered rats (Figure 1B). Blood pressure tended to decrease in CCCP-administered rats 135 
compared to vehicle-administered rats (p = 0.086, Figure 1C). Serial echocardiographic 136 
examination showed that both LVDd and LVDs increased (p = 0.0048 and 0.0047, 137 
respectively) and fractional shortening decreased (p = 0.0078) at 30 min after the CCCP 138 
injection (Figures 1D, 1E, and 1F, respectively), indicating that CCCP caused transient left LV 139 
dilatation and systolic dysfunction. The difference between CCCP-administered and vehicle-140 
administered rats was diminished at 90–180 min after the CCCP injection. 141 
 142 
CCCP changed substrate uptake in the cardiac tissue 143 
Next, we examined whether CCCP caused a change in the myocardial uptake of glucose and 144 
fatty acids using 18FDG and 125I-9MPA, respectively (Figure 2A). Compared to the vehicle 145 
group, glucose uptake showed a 95% increase (p = 0.033) and the fatty acid uptake showed a 146 
52% decrease (p = 0.033) 90 min after CCCP administration (Figures 2B and 2C, 147 




99mTc-MIBI washout increased in rats administered CCCP  150 
To investigate the effect of CCCP on membrane potentials in vivo, we obtained pre-CCCP or 151 
vehicle-administered images 15 min after the 99mTc-MIBI injection, then CCCP or vehicle 152 
was injected, and post-CCCP or vehicle-administered images were obtained 180 min after the 153 
99mTc-MIBI injection (Figure 3A). Myocardial retention of 99mTc-MIBI was markedly 154 
decreased after the CCCP injection (Figure 3B, lower panels) compared to that in vehicle-155 
administered rats (Figure 3B, upper panels). The analysis of in vivo images showed that the 156 
washout rate of 99mTc-MIBI was significantly increased in CCCP rats (p = 0.015; Figure 3C). 157 




In summary, CCCP caused transient LV dilatation and systolic dysfunction. CCCP increased 160 
glucose uptake, and decreased fatty acid uptake in the rat heart tissue and 99mTc-MIBI 161 
washout rate in vivo. 162 
 163 
We recently reported that the accumulation of 99mTc-MIBI signals was correlated to the 164 
tetramethylrhodamine ethyl ester assay in ex vivo perfused rat hearts [11]. We found that 165 
CCCP decreased the in situ ATP levels at 30 min after the injection [11], suggesting that 166 
energy deficiency might cause the LV dilatation and systolic dysfunction observed in the 167 
present study. This mechanism of the cardiac dysfunction is currently only speculative and 168 
was not directly elucidated in the present study; however, the effects of CCCP were transient 169 
according to the metabolic rate of CCCP. Dillis et al. [18] reported that hepatic ATP and co-170 
substrate levels decreased 30 min after CCCP injection and returned to normal at 60 min after 171 
the injection, which is consistent with the results of the present study. 9mTc-MIBI has a high 172 
affinity for the negative charges associated with membrane potentials across the 173 
mitochondrial membrane, according to the Nernstian equation [19,20]. A blood clearance 174 
study showed that myocellular equilibrium was reached at a t1/2 of 2–5 min in clinical use 175 
[21]. Therefore, the washout rate was increased according to the decreased membrane 176 
potentials. The observed increase in 99mTc-MIBI washout rate in the present study has the 177 
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possibility to represent, at least partly, a decrease in mitochondrial membrane potentials and 178 
dysfunction of mitochondria which support the CCCP-induced changes of the substrate 179 
uptake (Figure 2) and energy deficiency [11] in the heart.  180 
 181 
18FDG uptake increased in the present study. Although neither the metabolic rate of glycolysis 182 
nor the molecular mechanism for directly increasing 123FDG uptake was examined in the 183 
present study, a possible mechanism of this rapid regulation is adenosine monophosphate 184 
(AMP)-activated protein kinase. An increase of the AMP to ATP ratio, i.e. energy deficiency, 185 
activated AMP-activated protein kinase and enhanced glucose uptake and glycolysis [22]. By 186 
contrast, the uptake of 123I-9MPA decreased. 123I-9MPA was rapidly metabolized to 187 
iodophenyl-3-methylnonanoic acid (3MNA) by beta-oxidation, and was not further 188 
metabolized [23,24]; therefore, it is generally considered to reflect fatty acid oxidation in 189 
mitochondria [23,24]. Ikawa et al. reported the increased iodine-123-labelled 15-(p-190 
iodophenyl)-3-(R,S)-methylpentadecanoic acid (123I-BMIPP), another tracer of fatty acids, in 191 
patients with mitochondrial cardiomyopathy with the increase in 99mTc-MIBI washout ratio 192 
[25]. Most of the 123I-BMIPP was incorporated into the triglyceride pool, and reflects the 193 
turnover of the triglyceride pool in the cytosol [26]. In patients with mitochondrial 194 
cardiomyopathy, the energy production shifts from the metabolism of fatty acids to the 195 
glycolytic pathway with the excess of glycerol-3-phosphate, leading to the enhanced synthesis 196 
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of triglycerides. Thus, in chronic mitochondrial failure, 123I-BMIPP is incorporated more into 197 
triglyceride-pool and remains in triglyceride pool in the cytosol [26]. Thus, decreased uptake 198 
of 123I-9MPA reflects the acute mitochondrial dysfunction, and increased uptake (and 199 
decreased washout) of 123I-BMIPP reflects the chronic mitochondrial dysfunction. 200 
 201 
Life-long administration of low-dose chemical uncoupling 2,3-dinitrophenol to mice caused 202 
no adverse effects, decreased body weight, and prolonged survival [4][ 27]. However, the 203 
dose used in the present study caused LV dysfunction. One report showed that CCCP 204 
decreased hepatic ATP production when administered to rats at a dose of 4 mg/kg with no 205 
mortality, whereas a dose of 5 mg/kg resulted in 11% mortality [18]. The LD50 was found to 206 
be approximately 8 mg/kg. Hence, the dose of CCCP used in this short-term experiment is 207 
thought to be relatively high, indicating that high-dose CCCP is detrimental for cardiac 208 
function. The next key question is to determine to what dosage and for how long uncoupling 209 
would have to be increased to achieve beneficial effects due to decreased ROS production and 210 
to avoid detrimental effects due to decreased ATP production and heart failure.  211 
 212 
Limitations 213 
The limitations of the present study include the lack of an observed dose-response and the 214 
lack of a clear mechanism to explain the observed effects. Although the relationship between 215 
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99mTc-MIBI accumulation and mitochondrial potential was assessed in cultured myocytes 216 
[28], direct monitoring of the mitochondrial potential in vivo was also difficult to achieve; 217 
however, further studies about serial measurements of the phosphocreatine and ATP levels in 218 
vivo would provide useful information on the energy deficiency and its recovery in this 219 
model. Lack of measuring oxygen consumption rate in vivo is another limitation. Finally, we 220 
acknowledged that this work was a subsequent series of studies using CCCP [11], although 221 
the data in this work provided the insights on the changes in substrate uptake and function 222 
when we used CCCP.  223 
 224 
Conclusions 225 
The deleterious effects on cardiac function and the changes in substrate uptake were observed 226 
when administered with the protonophore at a high dose. 227 
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Figure legends 302 
Figure 1: Physiological and echocardiographic examination of CCCP-administered rats 303 
(A) Body temperature analyzed at 30 min after the CCCP injection was higher than that after 304 
vehicle injection. (B) Heart rate did not differ between CCCP-administered and vehicle-305 
administered rats (Vehicle: n = 6, CCCP: n = 6). (C) Blood pressure tended to decrease in 306 
CCCP-administered rats (116 ±4 mmHg) compared to vehicle-administered rats (131 ± 3 307 
mmHg). Vehicle: n = 6, CCCP: n = 6. (D) Left ventricular diastolic dimension (LVDd). 308 
Vehicle: n = 6, CCCP: n = 6. (E) Left ventricular systolic dimension (LVDs). (F) Fractional 309 
shortening (FS). Serial echocardiographic examination showed that both LVDs and LVDd 310 
increased and FS decreased up to 60 minutes after the CCCP injection. All circles and bars 311 
indicate means and SEMs respectively. *p < 0.05 versus vehicle-administered rats. 312 
 313 
Figure 2: The uptake of 18FDG was increased and the uptake of 125I-9MPA was 314 
decreased by CCCP. 315 
(A) A schema of the study for analyzing the extracted hearts. (B) and (C) The uptake of 316 
18FDG and 125I-9MPA, respectively. All bars indicate means and SEMs. *p < 0.05 versus 317 
vehicle-administered rats. n=6 in each group. 318 
 319 
Figure 3: 99mTc-MIBI washout was increased in rats administered CCCP 320 
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(A) A schema of the study for analyzing the images and extracted hearts. (B) Representative 321 
in vivo images of 99mTc-MIBI distribution. Myocardial retention of 99mTc-MIBI was markedly 322 
decreased after the CCCP injection (lower panels) compared to vehicle-administered rats 323 
(upper panels). White arrowheads indicate hearts. (C) Analysis of in vivo images showed that 324 
the 99mTc-MIBI washout rate was significantly increased in CCCP rats (Vehicle: n = 7, CCCP: 325 
n = 8). WR, washout rate. All bars indicate means and SEMs. *p < 0.05 versus vehicle-326 
administered rats. 327 
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